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Abstract: Defects in coordinated ribosomal RNA (rRNA) transcription in the nucleolus cause cellular
and organismal growth deficiencies. Bloom’s syndrome, an autosomal recessive human disorder
caused by mutated recQ-like helicase BLM, presents with growth defects suggestive of underlying
defects in rRNA transcription. Our previous studies showed that BLM facilitates rRNA transcription
and interacts with RNA polymerase I and topoisomerase I (TOP1) in the nucleolus. The mechanisms
regulating localization of BLM to the nucleolus are unknown. In this study, we identify the
TOP1-interaction region of BLM by co-immunoprecipitation of in vitro transcribed and translated
BLM segments and show that this region includes the highly conserved nuclear localization sequence
(NLS) of BLM. Biochemical and nucleolar co-localization studies using site-specific mutants show
that two serines within the NLS (S1342 and S1345) are critical for nucleolar localization of BLM but
do not affect the functional interaction of BLM with TOP1. Mutagenesis of both serines to aspartic
acid (phospho-mimetic), but not alanine (phospho-dead), results in approximately 80% reduction
in nucleolar localization of BLM while retaining the biochemical functions and nuclear localization
of BLM. Our studies suggest a role for this region in regulating nucleolar localization of BLM via
modification of the two serines within the NLS.
Keywords: Bloom’s syndrome; rRNA transcription; BLM; topoisomerase I; growth defects;
nucleolar localization
1. Introduction
Ribosomal RNA (rRNA) transcription plays a central role in ribosome biogenesis with rRNA an
integral part of ribosomal subunits [1–6]. The genes encoding rRNA (rDNA) are found in multiple
copies organized into tandem repeats; human cells contain more than 400 rDNA clusters of repeats,
each spanning 35 kb on the p-arms of the acrocentric chromosomes 13, 14, 15, 21 and 22. rDNA loci are
characterized by clusters of GC-repeats capable of forming aberrant structures during replication and
transcription, and undergoing intra- and inter-chromosomal recombination. Transcription of rDNA
genes is facilitated primarily by the RNA polymerase I complex in the nucleolus, with the 18S, 5.8S
and 28S rRNAs transcribed as a single pre-rRNA transcript that is subsequently processed prior to
the assembly of ribosomes [2,7–9]. The eukaryotic ribosome consists of a small (40S) and a large (60S)
subunit: the 40S subunit includes 18S rRNA and 33 ribosomal proteins; the 60S subunit includes 5S
rRNA, 28S rRNA, 5.8S rRNA and 46 ribosomal proteins [6–10]. Ribosome biosynthesis requires the
coordinated activity of three RNA polymerases, Pol I (for 5.8S rRNA, 18S rRNA and 28S rRNA), Pol II
(for mRNA encoding ribosomal proteins) and Pol III (for 5S rRNA), to synthesize rRNA and ribosomal
proteins in the required stoichiometric amounts for assembly into ribosomes [6,10,11].
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Ribosome biogenesis is critical for protein translation, cellular growth and proliferation. The group
of disorders termed ribosomopathies, characterized by defects in the ribosome biogenesis pathway and
including mutations in RNA polymerase I transcription complex components, results in severe growth
impairment [4,10,12,13]. Furthermore, dysregulation of rDNA metabolism is associated with nucleolar
dysfunction, cellular and organismal growth defects, and cellular transformation; it is often suggested
as a primary cause of cellular senescence [3,9,10,14–18]. Dysregulation of rDNA metabolism correlates
with rDNA repeat instability and compromised DNA damage responses throughout the genome.
Bloom’s syndrome (BS), an autosomal recessive human disorder caused by mutations of the
recQ-like helicase BLM, is associated with several characteristics of nucleolar dysfunction [19–24].
Individuals with BS display intra-uterine growth retardation and proportional dwarfism that persists
throughout life. BS is an extreme case of a ribosomopathy that presents the apparent paradox of
growth retardation, a consequence of hypo-activity of the nucleolus, and a high predisposition
to cancer, often associated with hyperactivity of the nucleolus [13]. The intersection of a growth
retardation phenotype and cancer induction is intriguing. Most, but not all, ribosomopathies
present with hematopoietic defects; however, the mechanisms underlying these defects are unclear.
It is thought that ribosome deficiency results in p53-induced apoptosis in rapidly proliferating
hematopoietic precursor cells, resulting in the observed clinical phenotypes. Differences in the clinical
phenotypes among various ribosomopathies could be due to differential protein expression and
thresholds for p53 activation among various tissues [13,25]. Treacher Collins syndrome, caused by
mutations in the treacle protein, presents with craniofacial defects similar to the classic ribosomopathy
Diamond-Blackfan anemia, but without hematologic abnormalities. A mouse model of Treacher Collins
syndrome recapitulates the ribosome deficiency and craniofacial abnormalities [26]; these craniofacial
abnormalities are rescued by inhibition of p53 [27]. Hematopoietic defects are not generally found
in those affected by BS, although an embryonic-lethal Blm knockout mouse model results in severe
anemia during embryogenesis [28]. Cells without BLM display impaired growth in tissue culture and
are characterized by elevated rDNA repeat instability, inter- and intra-chromosomal recombination,
recombination of acrocentric chromosome arms where rDNA is found, chromosomal breakage and
telomeric associations [19,20,22,29–31]. The mechanisms underlying the clinical growth defects of BS
remain unclear.
Several studies point to a nucleolar role of BLM in rDNA metabolism and stability. BLM localizes
to the nucleolus via the C-terminus and to promyelocytic leukemia (PML) nuclear bodies, implicated
in DNA repair mechanisms, via the N-terminus [32,33]. BLM functions as an ATP-dependent 3′–5′
helicase and aids in the resolution of unusual DNA structures associated with replication stress and
recombination especially for the GC-rich DNA sequences found in rDNA and at telomeres. BLM
directly associates with rDNA sequences, specifically with the 18S-coding and Alu-repeat regions;
its localization correlates with genomic stability [31,33]. BLM deficiency results in hyper-recombination
within rDNA [34]: BS cells display reduced overall rDNA repeat numbers in comparison to wild-type
cells. Furthermore, our recent studies demonstrate a role for BLM in facilitating rDNA transcription
in the nucleolus [35,36]. BLM physically interacts with several RNA polymerase I complex proteins,
including DNA topoisomerase I (TOP1), and accelerates rDNA transcription at least two-fold in vivo.
BLM is a component of active RNA polymerase I transcription complexes. Disruption of transcription
by the RNA polymerase I inhibitor actinomycin D re-distributes both RNA polymerase I components
and BLM from the nucleolus into the nucleoplasm. In vitro, BLM facilitates unwinding of RNA:DNA
hybrids (R loops) that have the potential to block ongoing rDNA transcription. This activity is enhanced
by its association with TOP1, another integral component of the rDNA transcription machinery [36].
TOP1 is localized in the nucleolus and facilitates rDNA transcription by removing superhelical tension
(relaxation) generated by ongoing transcription [37–39]. Our studies showed that BLM interacts with
TOP1 via the C-terminus and enhances its relaxation activity by 3–4 fold in vitro [36]. These studies
suggest collaborating functions of BLM and TOP1 in the nucleolus. They are also consistent with
the inhibition of RNA polymerase I transcription in yeast deficient for the BLM ortholog Sgs1 and
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Srs2, another 3′–5′ helicase, suggesting a conserved role for recQ-like helicases in nucleolar rRNA
transcription [40].
In addition to RNA polymerase I components, BLM interacts with several other proteins that
function in nucleolar metabolism, including nucleophosmin, DNA topoisomerase IIα (TOP2A),
WRN and BRCA1 [35,41–46]. BLM also interacts with p53, a major stress sensor that controls the cellular
response to nucleolar stress [10]. The functional implications of these interactions are unclear but
suggest a nucleolar specific role for BLM in regulating multiple aspects of rDNA metabolism, including
recombination, replication and transcription. Signals regulating nucleolar trafficking and/or targeting
of BLM and their underlying mechanism(s) are unknown. The goal of this study is to delineate these
signals within BLM with the long-term goal of understanding the basis of growth defects associated
with BS and developing therapeutic interventions that use nucleolar BLM to overcome growth defects
or prevent tumor growth. Our results map the TOP1-interaction region of BLM, identify specific amino
acids that control its nucleolar trafficking and functionally characterize the role of these amino acids
in BLM. Our results identify a putative phosphorylation mechanism that regulates nucleolar entry
(and exit) of BLM.
2. Materials and Methods
2.1. Cell Lines
GM08505 immortalized BS fibroblasts were obtained from Coriell Cell Repository (Camden,
NJ, USA). Cells were cultured in Minimum Essential Medium (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA) at 37 ◦C and 5% CO2.
2.2. Cloning
The pYES-BLM yeast expression vector was provided by Ian Hickson [47]. BLM deletion and
site-specific mutants were generated by an overlapping polymerase chain reaction (PCR) with the
pYES-BLM vector as a template using Phusion High-Fidelity DNA Polymerase (NEB, Ipswich, MA,
USA). 3′ internal primers were used with the 5′ external primer; 5′ internal primers were used with
the 3′ external primer. Corresponding products from both reactions were gel-purified (Qiagen, Hilden,
Germany) and used as templates in an overlapping PCR with the 5′ external and 3′ external primers in
a 1:1 ratio. Primers (5′–3′) used in BLM cloning were:
5′ external primer: CAGCTTTTGGCCTACTTTGGT
3′ external primer: TTCCTTTTCGGTTAGAGCGGA
3′ 1332-1349 deletion internal primer:
CCACTGGAAGCAGTTCTGGTTTTACTTGCAAAGTAGTGG
5′ 1332-1349 deletion internal primer:
CAAGTAAAACCAGAACTGCTTCCAGTGGTTCCAA
3′ S1342A/S1345A internal primer: CTCTTAGCCCTTTGGGCGGCTGG
5′ S1342A/S1345A internal primer: CCAGCCGCCCAAAGGGCTAAGAG
3′ S1342D/S1345D internal primer: CTCTTATCCCTTTGGTCGGCTGGC
5′ S1342D/S1345D internal primer: GCCAGCCGACCAAAGGGATAAGAG
3′ S1342A internal primer: CTCTTAGACCTTTGGGCGGCTGG
5′ S1342A internal primer: CCAGCCGCCCAAAGGTCTAAGAG
3′ S1345A internal primer: CTCTTAGCCCTTTGGGAGGCTGG
5′ S1345A internal primer: CCAGCCTCCCAAAGGGCTAAGAG
3′ S1342D internal primer: CTCTTAGACCTTTGGTCGGCTGGC
5′ S1342D internal primer: GCCAGCCGACCAAAGGTCTAAGAG
3′ S1345D internal primer: CTCTTATCCCTTTGGGAGGCTGGC
5′ S1345D internal primer: GCCAGCCTCCCAAAGGGATAAGAG
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All restrictions enzymes were purchased from NEB. Gel-purified PCR products and pYES-BLM
were digested with SalI and XbaI at 37 ◦C for 1.5 h per manufacturer’s instructions and gel-purified.
T4 DNA ligase (NEB) was used in ligation reactions per manufacturer’s instructions. Ligation reactions
were transformed into Dh5α-competent cells. Plasmids were purified with QIAprep Spin Miniprep
kit (Qiagen) and E.Z.N.A. Endo-Free Plasmid Maxi Kit (Omega Bio-tek, Norcross, GA, USA). The full
sequence of each BLM mutant was verified by the OSU Nucleic Acids Shared Resource. Inserts were
transferred into the pEGFP-BLM vector, originally generated by cloning BLM cDNA into a mammalian
expression vector containing an N-terminal GFP tag, pEGFP-C1 (Clontech, Mountain View, CA, USA).
The pYES-BLM mutants and pEGFP-BLM vector were digested with AflII and AsiSI at 37 ◦C for 1 h,
and the remaining steps were carried out as previously described.
TOP1 cDNA was purchased from Thermo Fisher Scientific (Waltham, MA, USA) as pCR4-TOPO
and sub-cloned into the pYES yeast expression vector. A SacI restriction site and His tag were added to
the 5′ end of the cDNA and a SalI site added to the 3′ end through PCR. Primers (5′–3′) used in TOP1
sub-cloning were:
5′ TOP1 primer: CGTAGAGCTCGGATCCCTAACCATGCACCACCACCACCACCACAGTG
GGGACCACCTC
3′ TOP1 primer: TACGCTCGAGTCAAAACTCATAGTCTTCATCAGCC
Gel-purified PCR products were digested sequentially with SalI at 37 ◦C for 1 h and SacI at 37 ◦C for
1 h and purified with QIAquick PCR Purification Kit (Qiagen) in between digests. pYES-BLM vectors
were digested with SacI and XhoI at 37 ◦C for 1 h. Remaining steps were carried out as previously
described. The full sequence of TOP1 cDNA was verified by the OSU Nucleic Acids Shared Resource.
2.3. In Vitro Transcription and Translation
In vitro transcription and translation (IVTT) reactions were performed with the TNT Rabbit
Reticulocyte Lysate kit (Promega, Madison, WI, USA) according to manufacturer’s instructions with
35S-methionine. Peptides generated with the included luciferase control DNA were used as a negative
control in subsequent immunoprecipitation reactions. DNA templates containing the indicated amino
acids of BLM were generated by PCR using pYES-BLM as a template. The ∆1332–1349 DNA template
was generated by PCR using the pYES-BLM-∆1332–1349 plasmid as a template. The T7 promoter and
a poly-A tail were added by PCR. PCR products were separated on agarose gels and purified with
a QIAquick gel extraction kit (Qiagen). IVTT products were incubated with full-length recombinant
TOP1 followed by α-TOP1 (A302-589A, Bethyl, Montgomery, TX, USA) or isotype control (rabbit IgG,
P120-201, Bethyl) antibodies at 4 ◦C for a total of 3 h with rotation in buffer containing 10 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1 mM DTT, 0.1% Tween-20, 0.1 mg/ml BSA and
protease inhibitor (Sigma-Aldrich, St. Louis, MO, USA). Complexes were immunoprecipitated with
Dynabeads Protein G (Invitrogen) at 4 ◦C for 2 h with rotation. Beads were washed 4 times for 5 min
at 4 ◦C with rotation, and products were eluted with SDS-PAGE sample buffer at 95 ◦C for 5 min and
separated by SDS-PAGE. Gels were dried, exposed to storage phosphor screens (GE, Fairfield, CT, USA),
imaged with Typhon FLA 7000 (GE) and analyzed using ImageQuant software (GE). The C-terminus
of BLM (amino acids 997–1417) was used as a positive control and luciferase as a negative control for
each experimental replicate. Peptide fragment pulldowns were quantified, and non-specific pulldown
by the IgG control antibody was subtracted. Each fragment was normalized to its input and expressed
as % relative IP compared to the positive control (amino acids 997–1417). Experiments were repeated
3 to 9 times per peptide. Data were analyzed with a Student’s t-test (Graphpad Software, La Jolla,
CA, USA).
2.4. Protein Purification
BLM was purified as previously described with the addition of a heparin-sepharose
column [35,36,44]. Briefly, His-tagged BLM (pYES-BLM-WT, pYES-BLM-∆1332–1349, pYES-BLM-
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S1342A/S1345A and pYES-BLM-S1342D/S1345D) and TOP1 (pYES-TOP1) were expressed in
Jel1 Saccharomyces cerevisiae. Yeast cells were lysed with a French Press Cell Disrupter (Thermo Fisher
Scientific), and cell debris was pelleted by ultracentrifugation at 65,000 g for 1 h at 4 ◦C. BLM protein
was purified from the lysate by FPLC using Ni-NTA Superflow (Qiagen), Heparin-Sepharose 6 Fast
Flow (Amersham Biosciences, Little Chalfont, UK) and Q-Sepharose (Sigma-Aldrich) columns with
dialysis between each column in 50 mM Tris-HCl (pH 7.5), 200 mM NaCl, 1 mM EDTA, 10% glycerol,
1 mM DTT, protease inhibitor (Sigma-Aldrich) and 100 mM PMSF. The purified protein was dialyzed
in 50 mM Tris-HCl (pH 7.5), 200 mM NaCl, 1 mM EDTA, 20% glycerol, 1 mM DTT, protease
inhibitor (Sigma-Aldrich) and 100 mM PMSF, snap frozen in liquid N2 and stored at −80 ◦C.
The BLM mutants eluted at similar salt concentrations as wild-type. TOP1 was purified similarly
to BLM by FPLC using Ni-NTA Superflow (Qiagen) followed by Heparin-Sepharose 6 Fast Flow
(Amersham Biosciences) columns with dialysis between columns. TOP1 eluted at 140–230 mM
imidazole from Ni-NTA, and at 610–670 mM NaCl from the Heparin-Sepharose column. Purified
TOP1 was dialyzed in 50 mM Tris-HCl (pH 7.5), 200 mM NaCl, 1 mM EDTA, 30% glycerol, 1 mM DTT,
protease inhibitor (Sigma-Aldrich) and 100 mM PMSF, snap frozen in liquid N2 and stored at −80 ◦C.
Single-band purity of the resulting proteins was verified by Coomassie blue staining of SDS-PAGE
gels. Protein concentration was measured using Qubit Protein Assay Kit (Thermo Fisher Scientific).
2.5. Helicase Assays
DNA oligonucleotides were purchased from Operon (Huntsville, AL, USA), and RNA




Oligonucleotides (DNA20 and RNA20) were end-labeled with 32P using polynucleotide kinase (NEB)
according to manufacturer’s instructions and annealed with the DNA33 oligonucleotide by heating to
95 ◦C for 5 min followed by slow cooling to room temperature (RT), to generate the corresponding
DNA:DNA or RNA:DNA substrates. Double-stranded substrate was separated on non-denaturing
polyacrylamide gels and gel-purified. Helicase assays were performed with the indicated concentration
of BLM protein and with the indicated substrate (DNA:DNA for protein activity determination or
RNA:DNA for TOP1 stimulation experiments) as previously described [35,36,48]. Briefly, BLM protein
was incubated with 2 fmol substrate, with and without a two-fold molar excess of TOP1, for 0.25, 0.5,
0.75, 1, 2, 3, 7 and 12 min at 37 ◦C in buffer containing 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 2 mM
MgCl2, 2 mM ATP, 1 mM DTT and 0.1 mg/mL BSA. Reactions were stopped at the respective times and
products separated on 12% non-denaturing polyacrylamide gels, dried, exposed to storage phosphor
screens (GE), imaged with Typhon FLA 7000 (GE) and analyzed using ImageQuant software (GE).
TOP1 alone did not unwind the RNA:DNA substrate (data not shown) [31]. Unwinding was quantified
as the amount of single-stranded substrate relative to the total substrate per time-point after subtracting
for single-stranded substrate in the minus BLM reaction. Substrate unwound (fmol) was plotted as a
function of time and curves fitted to hyperbolic plots corresponding to the Michaelis-Menten equation
with KaleidaGraph software (Synergy Software, Reading, PA, USA). Specific activities of the proteins,
in units of fmol substrate unwound/min/nM protein, were calculated as the slope of the line of the
initial unwinding rate plotted versus the protein concentration. Experiments were repeated 3 to 6 times
for each protein concentration. Helicase assays using recombinant TOP2A (purchased from TopoGEN,
Buena Vista, CO, USA) and BLM proteins were performed for 10 min at 37 ◦C in buffer containing 50
mM Tris-HCl (pH 8.0), 120 mM NaCl, 10 mM MgCl2, 1 mM ATP, 0.5 mM DTT and 50 µg/mL BSA,
using radioactively labeled DNA:DNA substrate prepared by annealing the following oligonucleotides,
as described [45]:
TTTTTTTTTTTTTTTTTAGGGTTAGGGCATGCACTAC
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GTAGTGCATGCCCTAACCCTAATTTTTTTTTTTTTTT
Reactions were terminated in TOP2A stop buffer (1% Sarkosyl, 5% Glycerol, 10 mM EDTA); products
were resolved on 10% non-denaturing polyacrylamide gels and quantified as described above.
2.6. Alignment and in Silico Phosphorylation Prediction
BLM protein sequences of different species were extracted from Ensembl and aligned using
ClustalW 1.83 through the European Bioinformatics Institute. The output was re-formatted in MView,
using default parameters. Identities were normalized by aligned length. Residues were colored by
identity and property. BLM amino acids 1332 to 1349 were analyzed with the following programs:
KinasePhos2.0 [49], NetPhorest [50], ScanSite3 [51], PPSP [52], Phosphonet [53], and SABLE for Relative
Solvent Accessibility (RSA) [54].
2.7. Immunofluorescence
GM08505 cells were plated on sterile coverslips and transfected with the indicated GFP-tagged
BLM plasmids (pEGFP-BLM-wild-type, pEGFP-BLM-D795A, pEGFP-BLM-S1342A/S1345A,
pEGFP-BLM-S1342D/S1345D, pEGFP-BLM-S1342A, pEGFP-BLM-S1345A, pEGFP-BLM-S1342D,
pEGFP-BLM-S1345D and pEGFP-BLM-∆1332–1349) with Lipofectamine2000 (Thermo Fisher Scientific)
according to the manufacturer’s instructions. Cells were fixed with 4% paraformaldehyde for 15 min
24-h post-transfection, washed with Dulbecco’s phosphate-buffered saline (DPBS) 3 times for 5 min,
permeabilized with 0.25% Triton-X-100 for 15 min, washed with DPBS 3 times 5 min and blocked
with 10% normal goat serum (Sigma-Aldrich) (all steps were performed at RT). Anti-nucleophosmin
(anti-B23, sc-47725, Santa Cruz, Dallas, TX, USA) was used at 1:1000, anti-PML (sc-966, Santa Cruz)
was used at 1:500 and Alexa-Fluor (Invitrogen) fluorescent goat anti-mouse was used at 1:2000 in
DPBS with 1% BSA (Sigma-Aldrich) and 0.1% Tween 20 (Sigma-Aldrich). Coverslips were mounted
with VectaShield plus DAPI mounting medium (Vector Labs, Burlingame, CA, USA). Slides were
imaged on a Zeiss AxioVert 200 M microscope and AxioCam MRm camera or an Olympus FV1000
filter confocal microscope. Nucleolar localization for 100 cells from 3 to 5 blinded experiments
was expressed as percent nucleolar localization. PML body localization for 50 cells from 3 blinded
experiments was expressed as percent PML body localization. Data were analyzed with a Student’s
t-test (Graphpad Software, La Jolla, CA, USA).
3. Results
3.1. BLM Amino Acids 1332–1349 Are Required for Binding to TOP1
Previous studies showed that BLM and TOP1 collaborate in facilitating rRNA transcription [35,36].
The two proteins directly interact and reciprocally stimulate each’s enzymatic function. Most likely,
this interaction promotes transcription, as in vitro TOP1 stimulates BLM helicase activity in unwinding
RNA:DNA duplexes resembling the R loops formed during rDNA transcription, while BLM stimulates
TOP1 activity in relaxation of helical tension generated in DNA during ongoing transcription [36].
To characterize these interactions, we identified the TOP1-interaction domain of BLM using
co-immunoprecipitation of full-length recombinant TOP1 (Figure S1) with 35S-methionine-labelled
BLM fragments generated by in vitro transcription and translation (IVTT). The BLM protein contains
a number of domains (Figure 1A), including the helicase domain (amino acids 672–985), the recQ
C-terminal domain (RQC, amino acids 1076–1181), that functions in DNA recognition and binding,
the helicase and RNase D C-terminal domain (HRDC, amino acids 1213–1292), that controls substrate
recognition, and a nuclear localization sequence (NLS, amino acids 1334–1349) [55]. Our earlier work
showed that the TOP1-interaction domain in BLM resides in the C-terminus (amino acids 997–1417) [36].
As the efficiency of IVTT of full-length BLM is poor due to its size, the C-terminal fragment (997–1417)
was used as a positive control for co-immunoprecipitation with full-length, purified TOP1 protein.
Luciferase was selected as a negative control. Sequential deletions were made within the 997–1417
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fragment of BLM, and each was tested for its ability to interact with TOP1 (Figure 1B). Results show
that deletion of amino acids 997–1119 at the N-terminus of this fragment or amino acids 1350–1417
at the extreme C-terminus of the fragment does not alter the ability of BLM to interact with TOP1
(Figure 1B, compare 997–1417 with 1120–1417 and 997–1349). Deletion of amino acids 1332–1417
reduced interaction with TOP1 to negligible levels (Figure 1B, compare 997–1349 with 997–1331),
indicating that TOP1 interaction requires amino acids 1332–1349. Amino acids 1332–1349 were
then deleted from the C-terminal fragment 997–1417 (yielding the fragment ∆1332–1349) to confirm
that amino acids 1332–1349 are required for TOP1 interaction (Figure 1B, compare 997–1417 with
∆1332–1349). Since this region also includes the BLM NLS, our results suggest an additional function
for the region in TOP1 interaction. The TOP1-interaction region is distinct from the TOP2A [44] and
DNA topoisomerase III alpha- (TOP3A) [56–58] interaction regions (Figure 1A).
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Figure 1. BLM amino acids 1332–1349 are required for binding to topoisomerase I. (A) Diagram of the
full-length BLM protein (1417 amino acids) highlighting known functional domains and the interaction
regions with topoisomerase I (TOP1), topoisomerase IIα (TOP2A) and topoisomerase IIIα (TOP3A).
An additional TOP3A-interaction region consisting of amino acids 1266–1417 was reported in one
study [56]; (B) 35S-methionine-labeled BLM peptide fragments of the indicated amino acids were
generated using IVTT, incubated with purified TOP1 and immunoprecipitated using α-TOP1 or isotype
control antibodies with Dynabeads Protein G. The C-terminus of BLM (amino acids 997–1417) was used
as a positive control and luciferase as a negative control for each replicate. Pulldown of each peptide
fragment was quantified and non-specific pulldown subtracted. Each fragment was normalized to
its input and expressed as % relative IP compared to the positive control (amino acids 997–1417).
Results from 3–9 experiments per peptide were compared to the positive control 997–1417 fragment
using a Student’s t-test. A representative gel is shown for each. Error bars depict standard deviation.
* p < 0.006, ** p < 0.001.
3.2. Deletion of Amino Acids 1332–1349 in BLM Abolishes TOP1-Mediated Unwinding of
RNA:DNA Substrate
Recombinant BLM proteins were generated and their specific activity evaluated in vitro to
confirm that BLM amino acids 1332–1349 are required for functional interaction with TOP1 (Figure 2).
BLM wild-type (WT), BLM-∆1332–1349 and TOP1 were expressed using yeast and purified (Figure S1).
Helicase activity of purified BLM proteins was measured using 32P-labeled double-stranded DNA
(dsDNA) substrate with a 13-base 3′ single-strand overhang. Initial unwinding rates for four protein
concentrations were graphed to calculate the specific activities of the proteins, expressed in fmol
substrate unwound/min/nM protein. BLM-∆1332–1349 unwound dsDNA with a lower specific
activity than BLM-WT (Figure S2, 1.5 vs. 2.9). Our previous studies demonstrated that TOP1 stimulates
BLM unwinding of R loop-like GC-rich RNA:DNA substrates in vitro [35,36]. To determine if amino
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acids 1332–1349 are required for this stimulation, we measured unwinding activity of BLM-WT
and BLM-∆1332–1349 on RNA:DNA substrates with and without a two-fold molar excess of TOP1.
The effect of TOP1 was measured at four different BLM protein concentrations based on the activity
of each protein. Consistent with previous studies, BLM-WT was stimulated 1.5-fold with TOP1
(Figure 2A,C and Figure S3) [36]. However, BLM-∆1332–1349 was not stimulated by TOP1 at
any protein concentration (Figure 2B,C and Figure S4). To verify that the loss of stimulation of
BLM-∆1332–1349 is specific to TOP1, we tested the ability of TOP2A to stimulate BLM helicase activity.
We previously demonstrated that TOP2A stimulates BLM unwinding of dsDNA and interacts with
the N-terminus of BLM (amino acids 489–587) [44] BLM-∆1332–1349 unwinding of dsDNA substrate
was stimulated approximately 3-fold by TOP2A, similarly to BLM-WT (Figure S5). Our results are
consistent with a requirement for amino acids 1332–1349 to facilitate a functional interaction of BLM




the  proteins,  expressed  in  fmol  substrate  unwound/min/nM  protein. BLM‐1332–1349 unwound 
dsDNA with a  lower specific activity  than BLM‐WT  (Figure S2, 1.5 vs. 2.9). Our previous studies 
demonstrated that TOP1 stimulates BLM unwinding of R  loop‐like GC‐rich RNA:DNA substrates 
in  vitro  [35,36].  To  determine  if  amino  acids  1332–1349  are  required  for  this  stimulation,  we 
measured unwinding activity of BLM‐WT and BLM‐1332–1349 on RNA:DNA substrates with and 
without a two‐fold molar excess of TOP1. The effect of TOP1 was measured at four different BLM 
protein  concentrations  based  on  the  activity  of  each  protein.  Consistent  with  previous  studies, 
BLM‐WT  was  stimulated  1.5‐fold  ith  TOP1  (Figures  2A,  2C  a d  S3)  [36].  However, 
BLM‐1332–1349 was  ot stimulated by TOP1 at any protein concentration (Figure  2B, 2C and S4). 
To verify that the loss of stimulation of BLM‐1332–1349 is specific to TOP1, we tested t e ability of 
TOP2A  to  stimulate  BLM  helicase  activity. We  previously  demonstrated  that TOP2A  stimulates 
BLM unwinding of dsDNA and  interacts with the N‐terminus of BLM (amino acids 489–587) [44] 
BLM‐1332–1349 unwinding of dsDNA substrate was stimulated approximately 3‐fold by TOP2A, 
similarly  to BLM‐WT  (Figure S5). Our  results are  consistent with  a  requirement  for  amino  acids 




Figure  2.  Unwinding  of  RNA:DNA  substrate  by  BLM‐1332–1349  is  not  stimulated  by  TOP1. 
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representative  protein  concentration,  0.2  nM  BLM‐WT  (A)  or  0.3  nM  BLM‐1332–1349  (B)  are 
shown. BLM protein with two‐fold molar excess TOP1 or equivalent volume of reaction buffer was 
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Figure 2. Unwinding of RNA:DNA substrate by BLM-∆1332–1349 is not stimulated by TOP1. Kinetics
of unwinding of RNA:DNA substrate was assessed using a range of BLM protein concentrations with
and without TOP1. Representative gels and kinetics of unwinding for one representative protein
concentration, 0.2 nM BLM-WT (A) or 0.3 nM BLM-∆1332–1349 (B) are shown. BLM protein with
two-fold molar excess TOP1 or equivalent volume of reaction buffer was incubated with 2 fmol
RNA:DNA substrate for 0.25, 0.5, 0.75, 1, 2, 3, 7 and 12 min at 37 ◦C, and double- an single-stranded
products were separated on non-denaturing acrylamide gels. Heat denatured (HD) s bstrate was
generated by heating at 95 ◦C for 5 min. Unwi ding was quantified as the amount of single-stranded
substrate generated compared to the total substrate per time-point. Experiments were repeated 3 to
6 times for each protein concentration, and curves showing amount of substrate unwound (fmol) as
a function of time were fitted to hyperbolic plots corresponding to the Michaelis-Menten equation.
Reactions with TOP1 alone were performed with each experiment to verify the lack of unwinding
ability of TOP1. Error bars depict standard deviation. (C) Specific activities of BLM proteins with and
without TOP1 were calculated by measuring initial unwinding rates for 4 protein concentrations (as in
panels A and B; Figures S3 and S4) and graphed as a function of protein concentration; specific activity
was calculated from the slope of the line (fmol substrate unwound/min/nM protein). Error bars depict
standard deviation.
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3.3. Amino Acids in the Region 1332–1349 Are Critical for Nucleolar Targeting of BLM
BLM normally localizes within PML nuclear bodies and the nucleolus [33]. In order to assess the
cellular consequences of deleting amino acids 1332–1349, GFP-tagged BLM constructs were transiently
expressed in a BS fibroblast cell line, GM08505. Nucleolar localization was monitored using BLM
co-localization with the nucleolar protein nucleophosmin (NPM). Studies with BLM-∆1332–1349
revealed that it localizes primarily outside the nucleus (Figure S6). The TOP1-interaction region
(1332–1349) also includes the arginine- and lysine-rich bipartite NLS, most likely preventing
BLM-∆1332–1349 from entering the nucleus. These data are consistent with previous analyses of
the NLS [59,60].
Therefore, a multiple alignment of the NLS and its flanking regions was compiled to assess
conservation of the amino acids within the TOP1-interaction region (Figure 3). Analyses demonstrate
that the arginine- and lysine-rich bipartite motifs are completely conserved among 19 selected
mammalian species. Although there is more variability in the composition of the other residues,
all of the included species contain one (drill, mouse, cow) to three (horse) serines in this region.
The dog and mouse sequences are notable in that each possesses a single threonine residue that aligns
with an otherwise completely conserved serine (human BLM S1342). It is known that physiological
functions of BLM are regulated by phosphorylation by several serine/threonine kinases [61]. The BLM
1332–1349 region was thus analyzed with multiple programs in silico to identify potential phosphorylation
sites. NetPhos2.0 identified S1342 and S1345 as putative phosphorylation sites with high probability
(score of 0.98); accessibility of this region to solvent was confirmed using SABLE. Multiple programs
predict that PKC or the DNA damage-sensitive kinases ATM and ATR are highly likely to phosphorylate
these residues. Given that this region is highly conserved among mammalian BLM proteins, these
analyses suggest that additional functions of the NLS in facilitating protein-protein interactions are
likely to be conserved (Figure 3). In the aligned region shown, the NLS sequences contain 1–3 serine
residues that are putative targets for post-translational modification by cellular kinases, including ATM,
PKA and AKT1, suggesting that these sites could control rDNA stability as well as cellular growth.
S1342 and/or S1345 were mutated to alanine (phospho-dead) or aspartic acid (phospho-mimic)
and tested for their ability to alter nucleolar localization using GFP-tagged constructs (Figure 4) or to
interact with TOP1 using purified proteins (Figure 5). The helicase-dead mutant of BLM (BLM-D795A)
was used as a control for mutation in a domain separate from TOP1 interaction. Co-localized foci were
quantitated and represented as percent nucleolar localization. BLM-WT and BLM-D795A localized
similarly to the nucleolus with about 60% of cells positive for nucleolar BLM. Alanine mutagenesis
of the two serines (BLM-S1342A/S1345A) does not significantly alter nucleolar localization of BLM
compared to BLM-WT or the helicase-dead mutant (Figure 4). In contrast, aspartic acid mutagenesis
of the serines (BLM-S1342D/S1345D) significantly reduces nucleolar targeting (p < 0.0001, Figure 4).
Mutagenesis of S1342 and S1345 to aspartic acid or alanine does not affect BLM localization to PML
bodies (Figure S7). Single mutants display similar patterns of nucleolar localization to corresponding
double mutants (p > 0.05; Figure S8). Our results suggest that S1342 and S1345 are critical for nucleolar
trafficking, but do not alter localization to the nucleus or PML bodies, and implicate the NLS region in
TOP1 interaction and nucleolar trafficking.
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Figure  3.  The  TOP1‐interaction  domain  of  BLM  is  highly  conserved  in mammals.  BLM  protein 
sequences  were  extracted  from  Ensembl  and  aligned  using  ClustalW  1.83  at  the  European 
Bioinformatics  Institute.  The  output  was  re‐formatted  in  MView,  using  default  parameters. 
Figure 3. The TOP1-interaction domain of BLM is highly conserved in mammals. BLM protein
sequences were extracted from Ensembl and aligned using ClustalW 1.83 at the European Bioinformatics
Institute. The output was re-formatted in MView, using default parameters. Identities are normalized
by aligned length. Residues are colored by identity and property. The TOP1-interaction region
is indicated with a black bar and corresponds to human BLM residues 1332–1349. Serines 1342
and 1345 are highlighted with arrows. The nuclear localization sequence (NLS) region of BLM is
contained within this region (1334–1349). The number in brackets at the end of each entry indicates
percentage identity of the full-length protein sequence with respect to the human BLM protein.
Consensus sequences for 90% and 100% identity are shown below. Accession numbers for the
sequences are as follows: human [Homo sapiens; NP_000048.1]; bonobo [Pan paniscus; XP_003807768.1];
chimpanzee [Pan troglodytes; XP_510594.2]; lowland gorilla [Gorilla gorilla gorilla; XP_004056835.1];
drill [Mandrillus leucophaeus; XP_011833777.1]; marmoset [Callithrix jacchus; XP_002749167.1]; grey
mouse lemur [Microcebus murinus; XP_012618727.1]; killer whale [Orcinus orca; XP_004278332.1];
horse [Equus caballus; XP_001502766.1]; Bactrian camel [Camelus ferus; XP_006192661.1]; bison
[Bison bison bison; XP_010839366.1]; cow [Bos Taurus; XP_613809.3]; domestic dog [Canis lupus
familiaris; XP_003434427.1]; domestic cat [Felis catus; XP_011281067.1]; polar bear [Ursus maritimus;
XP_008686016.1]; sheep [Ovis aries; XP_004017810.1]; chinchilla [Chinchilla lanigera; XP_005381562.1];
mouse [Mus musculus; NP_031576.4]; rat [Rattus norvegicus; XP_003753349.2].
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phospho‐dead  (BLM‐S1342A/S1345A)  and  phospho‐mimetic  (BLM‐S1342D/S1345D)  mutants. 
GM08505  BLM−/−  cells  were  plated  on  sterile  coverslips  and  transfected  with  the  indicated 
Figure 4. S1342 and S1345 determine nucleolar localization of BLM. (A) Cellular localization
of BLM phospho-dead (BLM-S1342A/S1345A) and phospho-mimetic (BLM-S1342D/S1345D)
mutants. GM08505 BLM−/− cells were plated on sterile coverslips and transfected with the indicated
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GFP-tagged BLM plasmids, BLM-WT, BLM-D795A (helicase dead), BLM-S1342A/S1345A and
BLM-S1342D/S1345D, using Lipofectamine 2000. Cells were fixed with 4% paraformaldehyde
24-h post-transfection, permeabilized with 0.25% Triton-X-100 and blocked with 10% normal goat
serum. Nucleoli were stained with anti-nucleophosmin (α-NPM) and Alexa-Fluor fluorescent
secondary antibodies and coverslips were mounted with VectaShield plus DAPI mounting medium.
(B) Quantification of nucleolar localization. Nucleolar localization for 100 cells from 4 to 5 blinded
experiments was expressed as percent nucleolar localization. Error bars depict standard deviation.
Results were compared to BLM-WT using a Student’s t-test (*** p < 0.0001).
3.4. Alanine or Aspartic acid Mutagenesis of S1342 and S1345 Does Not Alter the Functional Interaction of
BLM and TOP1
Recombinant mutant proteins BLM-S1342A/S1345A and BLM-S1342D/S1345D were purified
and characterized (Figures S1 and S2) and unwinding activities measured to assess whether S1342
and S1345 mutation alters TOP1 stimulation of BLM activity with RNA:DNA duplexes (Figure 5,
Figures S9 and S10). Results show that neither alanine nor aspartic acid mutations alter TOP1
stimulation of BLM compared to wild-type BLM (Figure 5) and suggest that these serines do not
affect the functional interaction of TOP1 and BLM but modify BLM nucleolar entry or exit.
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of BLM protein concentrations with and without TOP1. Representative gels and kinetics of
unwinding for one representative protein concentration, 0.2 nM, by BLM-S1342A/S1345A (A) or
BLM-S1342D/S1345D (B) are shown. BLM protein with two-fold molar excess of TOP1 or equivalent
volume of reaction buffer was incubated with 2 fmol RNA:DNA substrate for 0.25, 0.5, 0.75, 1, 2, 3, 7 and
12 min at 37 ◦C; double- and single-stranded products were separated on non-denaturing acrylamide
gels. Heat denatured (HD) substrate was generated by heating at 95 ◦C for 5 min. Unwinding was
quantified as the amount of single-stranded substrate compared to the total substrate per time-point.
Experiments were repeated 3 to 6 times for each protein concentration, and curves showing amount
of substrate unwound (fmol) as a function of time were fitted to hyperbolic plots corresponding
to the Michaelis-Menten equation. BLM-WT was used as a positive control for the ability of TOP1
to stimulate BLM (Figure 2). Reactions with TOP1 alone were performed with each experiment to
verify the lack of unwinding ability of TOP1. Error bars depict standard deviation. (C) Specific
activities of BLM proteins with and without TOP1 were calculated by measuring initial unwinding
rates for 4 protein concentrations (as in panels A and B; Figures S9 and S10) and graphed as a function
of protein concentration; specific activity was calculated from the slope of the line (fmol substrate
unwound/min/nM protein) (Figures S7 and S8). Error bars depict standard deviation. (D) Table
showing the fold-change of RNA:DNA unwinding activity of each BLM protein with TOP1. Specific
activities shown (fmol/min/nM) were obtained as in panel C and Figure 2C.
4. Discussion and Conclusions
Unlike nuclear localization sequences (NLS), nucleolar localization sequences are not clearly
defined. Both are composed of a high proportion of basic amino acids and may either be distinct or
overlap within any one protein [62]. Known mechanisms that localize proteins to the nucleolus include
protein-protein interactions with a nucleolar protein, protein-rDNA or protein-rRNA interactions
and protein-small nucleolar RNA interactions [63,64]. BLM binds rDNA via its C-terminus; regions
overlapping the RQC (amino acids 1118–1164) and HRDC domains (amino acids 1166–1331) mediate
these interactions [31–33]. The C-terminus (amino acids 997–1417) likewise mediates the interaction
of BLM with TOP1, also enriched in the nucleolus [35,36]. The data presented here further refine
the TOP1-interaction domain of BLM. We show that the region necessary for physical and functional
interaction with TOP1 resides within residues 1332–1349 (Figures 1 and 2). The TOP1-interaction region
of BLM is distinct from the TOP2A- and TOP3A-interaction regions of BLM, as well as the residues
directing BLM localization to PML bodies, primarily within the N-terminus [33,43,44,56–58,65].
Consequently, deletion of the TOP1-interaction region of BLM does not impair the functional interaction
with TOP2A (Figure S5). One study [56] suggested an additional TOP3A-interaction region in the
C-terminus of BLM (amino acids 1266–1417) that overlaps with the TOP1-interaction region; the effect
of the deletion of 1332–1349 or mutations within this region (S1342 and S1345) on the TOP3A interaction
is unclear. The TOP1-interaction region includes the NLS (1334–1349), a lysine- and arginine-rich basic
region that is highly conserved among mammalian BLM homologues (Figure 3). We also demonstrate
that S1342 and S1345 are critical for BLM nucleolar trafficking (Figure 4). While mutation of the
serines to alanine does not change BLM function or localization, their mutation to phospho-mimic,
aspartic acids, results in a dramatic reduction in nucleolar localization but not in nuclear localization,
PML body localization or functional interaction with TOP1 (Figures 4 and 5, Figure S7). Given that
both the rDNA binding domains of BLM are intact in these mutants, our results argue that the effect
of the phospho-mimetic modification in limiting nucleolar localization is dominant over the effects
of any rDNA transactions or TOP1 interactions that might direct BLM to the nucleolus. Unimpaired
localization of these mutants to PML bodies suggests that they would retain BLM functions in global
DNA repair. The ability of the BLM NLS to direct TOP1 functional interactions as well as modulate
nucleolar trafficking adds to the known functions of the BLM NLS.
Several studies have identified distinct sites within BLM that are modified post-translationally by
phosphorylation, ubiquitination and sumoylation in response to cellular stress [61]. These modifications
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alter its physiological functions, its associations with numerous protein partners, localization
to damaged sites upon stress or to PML bodies, chromatin localization, mitotic function or its
stability [66–84]. Due to their highly repetitive nature and GC-rich regions, rDNA loci are prone
to the formation of aberrant structures and damage that pose blocks to ongoing replication and
transcription. BLM is an integral part of DNA damage repair pathways that promote resolution of
such aberrant structures. In its absence or inappropriate localization, these transcription/replication
blocks could elicit a DNA damage response that without BLM would increase recombination between
rDNA repeats.
Accumulating evidence suggests a sub-nuclear spatial separation of the different aspects of
rDNA metabolism—transcription, replication and recombination—to ensure stability of the rDNA loci.
Early replicating rDNA loci (transcriptionally active) localize at the nucleolar periphery or outside the
nucleolus during early S-phase and are subsequently internalized in the nucleolus [85]. Replication of
transcriptionally silent rDNA loci occurs during mid- to late-S phase inside the nucleolus. Likewise,
during recombinational-repair of double-strand breaks, there is a transient translocation of rDNA loci
from the nucleolus to the nucleoplasm accompanied by a coordinated localization of recombination
proteins to the nucleoplasm [86–89]. In contrast, rDNA transcription by RNA polymerase I is localized
solely within the nucleolus. The dynamics of rDNA loci during the replication/transcription processes
may preserve rDNA loci stability by preventing collisions of the transcriptional and replication
machinery [85,88]. Serine modifications in the BLM NLS, potentially through phosphorylation,
and the resulting change in BLM nucleolar trafficking presents an efficient mechanism for facilitating
maintenance of rDNA loci by BLM. Likewise, restricting nucleolar entry of BLM may facilitate slower
rates of rDNA transcription and the ensuing ribosome biogenesis, perhaps favorable under conditions
of starvation or stress [6,9,13,35,36]. Several of the kinases predicted to phosphorylate BLM S1342
and S1345 and its orthologues (PKC, PKA and AKT) are sensitive to growth factors and regulate cell
growth pathways. Our results suggest further study of the specific kinase-phosphatase pairs that may
regulate BLM nucleolar trafficking. Such studies may also identify therapeutic strategies to modify
BLM localization to control cell growth while preserving extra-nucleolar functions of BLM.
Supplementary Materials: The following are available online at www.mdpi.com/2073-4425/7/9/69/s1.
Figure S1: Purification of recombinant BLM and TOP1 proteins. His-tagged BLM and TOP1 proteins were
expressed in yeast and purified to homogeneity as described previously [36]. Protein purity is demonstrated by a
single band using 8% SDS-PAGE and Coomassie Brilliant Blue staining.
Figure S2: Specific activity of purified BLM proteins. Kinetics of unwinding of DNA:DNA substrate were
assessed using a range of BLM protein concentrations. Representative gels (A) and unwinding kinetics (B) for one
representative protein concentration (0.3 nM) are shown for BLM-WT, BLM-∆1332–1349, BLM-S1342A/S1345A
and BLM-S1342D/S1345D. BLM protein was incubated with 2 fmol DNA:DNA substrate for 0.25, 0.5, 0.75, 1, 2,
3, 7 and 12 min at 37 ◦C; double- and single-stranded products were separated on non-denaturing acrylamide
gels. Heat denatured (HD) substrate was generated by heating at 95 ◦C for 5 min. Amount of substrate unwound
(fmol) was plotted as a function of time (minutes) and curves fitted to hyperbolic plots corresponding to the
Michaelis-Menten equation. Experiments were repeated 3 to 6 times for each protein concentration. Error
bars depict standard deviation. (C) Specific activities of BLM-WT, BLM-∆ 1332–1349, BLM-S1342A/S1345A
and BLM-S1342D/S1345D were calculated by measuring initial unwinding rates for 4 protein concentrations
and graphed as a function of protein concentration; specific activity was calculated from the slope of the line
(fmol substrate unwound/min/nM protein). Error bars depict standard deviation. (D) Table showing summary
of DNA:DNA unwinding activity of each BLM protein.
Figure S3: Unwinding of RNA:DNA substrate by BLM-WT is stimulated by TOP1. Changes in BLM-WT
activity with a RNA:DNA substrate by TOP1 was assessed by quantifying the unwinding as a function of time
using a range of BLM protein concentrations with and without TOP1, as in Figure 2A. Curves were fitted to
hyperbolic plots corresponding to the Michaelis-Menten equation.
Figure S4: Unwinding of RNA:DNA substrate by BLM-∆1332–1349 is not stimulated by TOP1. Changes in
BLM-∆1332–1349 activity with a RNA:DNA substrate by TOP1 was assessed by quantifying the unwinding as a
function of time using a range of BLM protein concentrations with and without TOP1, as in Figure 2B. Curves were
fitted to hyperbolic plots corresponding to the Michaelis-Menten equation.
Figure S5: Unwinding of DNA:DNA substrate by BLM-∆1332–1349 is stimulated by TOP2A. Unwinding of
DNA:DNA substrate was assessed using protein concentrations yielding similar unwinding activities (0.08 nM
BLM-WT or 0.13 nM BLM-∆1332–1349), with 7 nM TOP2A. Reactions were stopped after 10 min, and double- and
single-stranded products were separated on non-denaturing acrylamide gels. Unwinding was quantified as
the amount of single-stranded substrate generated compared to the total substrate, and results represented as
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fold-change relative to minus TOP2A. Experiments were repeated 4 times. BLM-WT and BLM-∆1332–1349 were
similarly stimulated by TOP2A (ns, not significant; p > 0.05). Error bars depict standard deviation. Statistical
comparisons were made using a Student’s t-test.
Figure S6: BLM-∆1332–1349 does not localize to the nucleus. GM08505 BLM−/− cells were transfected
with the indicated GFP-tagged BLM plasmids, BLM-WT and BLM-∆1332–1349, using Lipofectamine 2000. Cells
were fixed with 4% paraformaldehyde 24-h post-transfection, and coverslips mounted with VectaShield plus
DAPI-mounting medium. The figure shows that while BLM-WT localizes to the nucleus, BLM-∆1332–1349
localizes primarily outside the nucleus with an insignificant number of foci within the nucleus.
Figure S7: S1342 and S1345 do not affect PML body localization of BLM. (A) Cellular localization of
BLM phospho-dead (BLM-S1342A/S1345A) and phospho-mimetic (BLM-S1342D/S1345D) mutants. GM08505
BLM−/− cells were plated on sterile coverslips and transfected with the indicated GFP-tagged BLM plasmids,
BLM-WT, BLM-S1342A/S1345A and BLM-S1342D/S1345D, using Lipofectamine 2000. Cells were fixed with
4% paraformaldehyde 24-h post-transfection, permeabilized with 0.25% Triton-X-100 and blocked with 10%
normal goat serum. PML bodies were stained with α-PML and Alexa-Fluor fluorescent secondary antibodies,
and coverslips were mounted with VectaShield plus DAPI mounting medium. (B) Quantification of PML body
localization. Co-localization of BLM and PML for 50 cells from 3 blinded experiments was expressed as percent
PML body localization. All proteins had similar patterns of localization (ns, not significant; p > 0.05). Error bars
depict standard deviation. Statistical comparisons were made using a Student’s t-test.
Figure S8: Nucleolar localization of BLM is affected by phospho-mimetic mutagenesis of BLM-S1342
and/or BLM-S1345. GM08505 BLM−/− cells were transfected with the indicated GFP-tagged BLM plasmids,
BLM-WT, BLM-D795A (helicase dead), BLM-S1342A/S1345A, BLM-S1342A, BLM-S1345A, BLM-S1342D/S1345D,
BLM-S1342D, BLM-S1345D and empty vector using Lipofectamine 2000. Nucleolar localization of BLM mutants
for 100 cells from 3 to 5 blinded experiments was expressed as % nucleolar localization, as in Figure 4. BLM
proteins with mutated S1342D, S1345D and S1342D/S1345D amino acids demonstrated significant differences in
nucleolar localization compared to BLM WT, p < 0.001, p < 0.001 and p < 0.0001, respectively. However, single
BLM mutants of either alanine or aspartate presented similar patterns of nucleolar localization to their cognate
double mutants (ns, not significant; p > 0.05). Error bars depict standard deviation. Statistical comparisons were
made using a using a Student’s t-test.
Figure S9: Unwinding of RNA:DNA substrate by BLM-S1342A/S1345A is stimulated by TOP1. Changes in
BLM-S1342A/S1345A activity with a RNA:DNA substrate by TOP1 was assessed by quantifying the unwinding
as a function of time using a range of BLM protein concentrations with and without TOP1, as in Figure 5A.
Curves were fitted to hyperbolic plots corresponding to the Michaelis-Menten equation.
Figure S10: Unwinding of RNA:DNA substrate by BLM-S1342D/S1345D is stimulated by TOP1. Changes in
BLM-S1342D/S1345D activity with a RNA:DNA substrate by TOP1 were assessed by quantifying the unwinding
as a function of time using a range of BLM protein concentrations with and without TOP1, as in Figure 5B.
Curves were fitted to hyperbolic plots corresponding to the Michaelis-Menten equation.
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